CN112342215B - 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 - Google Patents
一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 Download PDFInfo
- Publication number
- CN112342215B CN112342215B CN202011255641.3A CN202011255641A CN112342215B CN 112342215 B CN112342215 B CN 112342215B CN 202011255641 A CN202011255641 A CN 202011255641A CN 112342215 B CN112342215 B CN 112342215B
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- sgrna
- gene
- mstna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 49
- 108091027544 Subgenomic mRNA Proteins 0.000 title claims abstract description 42
- 241000252498 Ictalurus punctatus Species 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000012216 screening Methods 0.000 title claims abstract description 14
- 241000252212 Danio rerio Species 0.000 claims abstract description 12
- 235000013601 eggs Nutrition 0.000 claims abstract description 8
- 108091033409 CRISPR Proteins 0.000 claims description 18
- 238000012408 PCR amplification Methods 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 14
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 238000010354 CRISPR gene editing Methods 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 238000000520 microinjection Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 42
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 239000000047 product Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 101150048453 MSTN gene Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 4
- 108010056852 Myostatin Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000019249 Growth/differentiation factor 8 Human genes 0.000 description 1
- 108050006583 Growth/differentiation factor 8 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 101150004578 gdf-8 gene Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法,通过设计CRISPR序列,制备包含目标基因的PCR扩增产物并将其与载体连接,再通过体外转录方法制备sgRNA,将所述sgRNA、所述包含目的基因的质粒和Cas9蛋白显微注射斑马鱼受精卵,以斑马鱼受精卵作为反应器筛选靶向敲除斑点叉尾鮰mstna基因的sgRNA序列。本发明首次以斑马鱼受精卵作为反应器筛选出编辑斑点叉尾鮰mstna基因的sgRNA序列,特异性强且敲除效率高,敲除流程简单快捷,为后续解析斑点叉尾鮰mstna基因功能提供动物材料。
Description
技术领域
本发明属于斑点叉尾鮰基因编辑技术领域,具体设计一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法。
背景技术
CRISPR/Cas***是存在于细菌和古细菌中的获得性免疫防御***,当细菌遭受病毒的侵染时,会在自身基因组里留下外源基因片段作为“记忆抗体”以识别再次侵入的病毒。CRISPR/Cas***由CRISPR(clustered regularly interspaced short palindromicrepeats)元件和编码一系列Cas蛋白的基因组成,其中CRISPR元件由多个相同的重复序列(repeat)与不同的间隔序列(spacer)交替排列组成。CRISPR/Cas9是CRISPR/Cas***中应用最为广泛的一种类型,Cas蛋白由单一的Cas9蛋白构成,Cas9蛋白主要功能的发挥依赖于:(1)Cas9在细菌内需要crRNA和反式激活RNA(trans-activating crRNA,tracrRNA)共同引导其靶向目标序列,现基因工程中已将两个RNA分子进行适当改造,序列整合为一条单链引导RNA(single guide RNA,sgRNA);(2)Cas9特异性识别靶向DNA3’端的3~7bp的碱基对,即PAM(protospacer adjacent motif)区。现由于gRNA设计合成方便,且此***对靶基因敲除效率的高效性,使得CRISPR/Cas9***被广泛应用于细胞与动物模型的遗传学改造。
肌肉生长抑制素(Myostatin,MSTN)又称生长/分化因子8(growth anddifferentiation factor,GDF8),转化生长因子β(transforming growth factor,TGF-β)超家族成员,是脊椎动物肌肉生长的负调节因子。McPherron等(1997)首次报道了小鼠mstn基因的缺失产生了典型的超肌表型。mstn基因的突变导致双肌表型这一现象在牛和绵羊等物种中均有报道。以mstn基因为靶位点的基因编辑动物模型具有更多的肌细胞和更快的生长速度,较多基于ZFNs、TALEN或CRISPR/Cas9介导的基因编辑研究也证实了这一点。此外,阻断mstn基因激活信号通路被认为是提高肌肉产量的另外一种策略。许多MSTN蛋白结合抗体或抑制肽也被认为具有阻断成熟肌肉生长抑制素信号通路以增加肌肉产量的功能。如何利用CRISPR/Cas9对斑点斑点叉尾鮰mstna基因进行有效编辑是需要解决的技术难题。
发明内容
发明目的:为了克服现有技术中存在的不足,本发明提供一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法。
技术方案:为实现上述目的,本发明提供的技术方案:一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列的筛选方法,其包括,设计CRISPR序列,所述CRISPR序列如序列SEQNO.1~SEQ NO.8所示;用所述CRISPR序列制备含目标基因片段的PCR扩增产物,制备目标基因的PCR扩增产物,所述目标基因片段如序列SEQ NO.9所示;将所述含目标基因片段的PCR扩增产物与载体连接、转化后筛选阳性转化子,经克隆摇菌并抽提出包含目的基因的质粒;根据设计的CRISPR序列,用体外转录方法制备sgRNA;将所述sgRNA、所述包含目的基因的质粒和Cas9蛋白显微注射斑马鱼受精卵,以斑马鱼受精卵作为反应器筛选编辑斑点叉尾鮰mstna基因的sgRNA序列。
优选的,所述sgRNA,其序列包括SEQ NO.21~SEQ NO.28中所示的一种或几种。
优选的,所述用体外转录方法制备sgRNA,其使用的正向引物序列包括序列SEQNO.12~SEQ NO.19中所示的一种或几种。
优选的,所述经克隆摇菌并抽提出包含目的基因的质粒,其使用的引物序列包括序列SEQ NO.10、SEQ NO.11中所示的一种或几种。
优选的,所述显微注射,其使用的所述sgRNA在注射液中的终浓度为100ng/μL,Cas9蛋白的终浓度为250ng/μL。
作为本发明的另一方面,本发明提供一种用于靶向敲除斑点叉尾鮰mstna基因的序列,其包括,CRISPR序列,包括序列SEQ NO.4、SEQ NO.8中所示的一种或几种;引物,包括序列SEQ NO.10~SEQ NO.20中所示的一种或几种;以及,sgRNA序列,包括序列SEQ NO.21~SEQ NO.28中所示的一种或几种。。
本发明的有益效果如下:
本发明首次在斑点叉尾鮰中筛选出有效编辑mstna基因的sgRNA序列,根据筛选出的CRISPR序列制备的sgRNA特异性强且敲除效率高,敲除流程简单快捷,可为后续解析斑点叉尾鮰mstna基因功能提供动物材料。
附图说明
图1为扩增的目标基因组DNA片段电泳结果图;
图2为纯化后sgRNA体外转录模板的电泳结果图;
图3为体外合成制备的sgRNA质量电泳鉴定结果图;
图4为mstna基因敲除效率鉴定的PCR扩增产物电泳结果图;
图5为突变检测的CRISPR4典型峰;
图6为突变检测的CRISPR8典型峰。
具体实施方式
下面结合附图对本发明作更进一步的说明。
实施例1:
本实施例的目的是设计敲除斑点叉尾鮰mstna基因的CRISPR,根据蛋白质的保守结构功能域,本次实验将设计在最后一个外显子(exon3)序列区域上设计8个CRISPR进行活性CRISPR筛选。该基因的CRISPR设计采用人工方法。其候选脱靶预测采用将CRISPR序列与GenBank中的目标基因组序列通过BLAST比对的方法实现。
表1基于mstna基因设计的CRISPR序列
2、PCR扩增目标基因组DNA片段
这一段斑点叉尾鮰基因序列在斑马鱼基因组数据库中没有找到有同源基因。该基因将以斑点叉尾鮰基因组DNA为模板进行克隆或采用直接合成方法得到。
1)目标基因组序列SEQ NO.9:
TTGTCATACCTTATCTGCCGAGCTTATGCCTTGGTAGTGTTTATAACTCTCTGAAGAAATGTTGCATGTCACCTCTTTCTCCTTTTGAATCCTATTTTCGCAGCAACCGTTCCTAGAGGTCAAAATCACCGAGGTGCCGAAGCGCTCCAGACGAGAATCCGGCCTCGACTGCAACGAGCTCTCTTCAGAACCCCGCTGCTGCCGTTACCCGCTCACTGTAGACTTTGAGGACTTTGGTTGGGACTGGATCATTGCGCCCAAGCGGTACAAGGCTAACTACTGCTCGGGCGAGTGCGAGCAGGTCGACGCGCAGAAGTTCCCACACTGGCACCTGGTGAACAAGGCAAACCCGCGAGGTACGGCCGGACCCTGCTGCACGCCCACCAAAATGTCCCCCATCAACATGCTCTACTTCAACCACCGAGAGCAGATCATCTACGGGAAGATCCCTTCTATGGTCGTGGATCTCTGTGGCTGCAACTGA。
2)PCR扩增的引物设计
表2 mstn基因片段扩增引物
3)PCR反应体系及条件
PCR反应体系(40μL):2×Mastermix(诺唯赞)20μL、16μL的超纯水、1μL的正反向(mstna-F1和mstna-R1)引物(5μM)和2μL的由客户提供的斑点叉尾鮰基因组DNA模板。
PCR反应条件:96℃3min,35×(96℃30s,60℃30s,72℃30s),72℃10min,4℃保存。
PCR产物电泳结果如图1,自左向右第2泳道为DNA Marker:从下向上依次为100bp、250bp、500bp、750bp、1000bp、2000bp、3000bp、5000bp;第1泳道为PCR外侧扩增产物。
4)PCR产物回收
将上述PCR产物利用无核酸酶污染的PCR clean up(Axygen)试剂盒收集。将38μLPCR外侧扩增产物与无核酸酶污染的Buffer PCR-A 114μL混合后,置于回收柱后12,000g,离心1min,弃去废液后,加入Buffer W2,12,000g,离心1min,弃去废液后,重复该步骤,弃去废液后,12,000g,空甩离心1min,最后加入回收溶剂为无核酸酶污染的DEPC水(南京尧顺禹生物公司),回收体积均为30μL。
5)目标基因PCR扩增产物的重组
将回收的PCR扩增产物连接入pGEM-T Easy载体(5μL总体积的反应),反应组成为:
反应时间为:室温孵育60min
6)转化
将上述5μL连接产物用50μL大肠杆菌DH5α感受态细胞(pfu≥108)进行转化。然后涂布于含氨苄(50μg/mL)的LB板,37℃下倒置培养过夜。
7)目标基因片段的重组子筛选
(1)PCR模板的快速制备:所涂平板,以10μL无菌枪头各随机挑选8个克隆。分别将其放入含20μL液态LB的PCR 8联管中,快速手工混匀,用作PCR的模板。
(2)PCR验证体系反应组成
反应体系一:
反应体系二:
(3)PCR反应条件:95℃3min,35×(95℃30s,56℃30s,72℃40s),72℃10min,4℃保存。
(4)转化子的测序
经过上述PCR验证,将阳性转化子经商业公司测序,测序引物T7,得到正确克隆3个,选取其中一个克隆摇菌并抽提出质粒(浓度252ng/μL,OD值:1.91)
实施例2:sgRNA体外转录
1、sgRNA模板的制备(PCR法)
PCR引物,正向引物序列如下:
表3正向引物序列
反向引物(为通用引物)R-Common:AAAAAAAGCACCGACTCGGTGCCAC,SEQ NO.20。
PCR反应体系(80μL):2×Mastermix(诺唯赞)40μL、35μL的超纯水、2μL的正向(mstna-sgRNA(1~8)-F分别和R-Common)引物(5μM)和1μL的pYSY-sgRNA质粒(10ng/μL)。
PCR反应条件:95℃3min,35×(95℃30s,56℃30s,72℃30s),72℃10min,4℃保存。
2、sgRNA体外转录模板的纯化
将上述PCR产物利用无核酸酶污染的PCR clean up(Axygen)试剂盒收集。回收溶剂为无核酸酶污染的超纯水(南京尧顺禹生物公司),回收体积均为14μL。分别取1μL进行琼脂糖凝胶(1%)电泳,检测回收质量。
自左向右第9泳道为DNA Marker:从下向上依次为100bp、250bp、500bp、750bp、1000bp、2000bp、3000bp、5000bp;第1~8泳道为mstna-sgRNA1~8纯化后的sgRNA体外转录模板。
3、sgRNA的体外转录
1)体外转录过程
将步骤3.1所得到的纯化后模板用T7 RNA聚合酶进行体外转录。使用RNA体外转录试剂盒(MAXIscript SP6/T7,Ambion,USA),按试剂盒说明书要求依次加入10×Transcription Buffer 2μL、10mM ATP 1μL、10mM CTP 1μL、10mM GTP 1μL、10mM UTP 1μL、T7 RNA polymerase mix 2μL、模板DNA 12μL,轻弹混匀离心后,37℃水浴1h。
加入DNase I(Ambion,USA)1μL,37℃水浴15min,以去除模板。之后加入80μL DEPC水扩大体积至100μL,同时加入10μL无核酸酶3M醋酸钠(pH 5.2)和3倍体积的无水乙醇(分析纯),-80℃沉淀过夜。4℃12,000g离心20min,去除上清后,加入无核酸酶75%乙醇,4℃12,000g离心20min,去除上清后,沉淀在通风橱晾干,然后以12μL无核酸酶超纯水重悬后储存于-80℃冰箱备用。
2)sgRNA质量的电泳鉴定
分别取1μL进行琼脂糖凝胶电泳(1%)鉴定其完整性,结果如图3,图中自左向右第1泳道为DNA Marker:从下向上依次为100bp、250bp、500bp、750bp、1000bp、2000bp、3000bp、5000bp;第2~9泳道依次为mstna-sgRNA1~8。
3)sgRNA浓度测定,结果如下表3
表4 sgRNA浓度测定结果
表5 sgRNA序列
实施例3:斑马鱼受精卵的显微注射
1、按常规方法收取斑马鱼受精卵。将上述sgRNA奇数(1、3、5、7)、sgRNA偶数(2、4、6、8)分为2组(终浓度约为100ng/μL)分别和斑点叉尾鮰mstna基因片段克隆质粒(终浓度约为50ng/μL)与Cas9蛋白(终浓度为200ng/μL)混合后,显微注入斑马鱼受精卵,注射量为1nL每胚胎。
2、斑马鱼胚胎DNA提取:待注射胚胎发育至24hpf时,2组每组分别取16枚胚胎单胚胎制备基因组DNA模板(共32枚胚胎样品),使用本公司生产的《斑马鱼基因型鉴定试剂盒》制备基因组DNA模板,具体反应条件为:65℃30min,95℃5min,16℃1min,4℃保存。
3、PCR扩增反应体系(30μL)
PCR体系:2×Mastermix(Vazyme)15μL、11μL的超纯水、1μL的正反向(mstna-F1和mstna-R1)引物(5μM)、和2μL的由3.4.1制备好的基因组DNA模板。
PCR反应条件
PCR反应条件为:95℃3min,30×(95℃30s,60℃30s,72℃30s),72℃10min,4℃保存。
4、PCR产物电泳结果
分别取2μL进行琼脂糖凝胶电泳(1%)鉴定其完整性,斑点叉尾鮰mstna基因敲除效率鉴定的PCR扩增产物电泳结果图如图4,第9泳道为DNA Marker:从下向上依次为100bp、250bp、500bp、750bp、1000bp、2000bp、3000bp、5000bp。第一行为斑点叉尾鮰mstna基因偶数组sgRNA活性鉴定的PCR扩增产物电泳结果;第二行为斑点叉尾鮰mstna基因奇数组sgRNA活性鉴定的PCR扩增产物电泳结果。
上述PCR产物经过电泳确认条带大小后,将阳性扩增产物(选送8个)送商业公司测序,测序引物mstna-F1/R1,测序结果如下:
sgRNA偶数(1、3、5、7)组,共反馈16个测序结果,都没有出现明显的Indel突变;sgRNA奇数组(2、4、6、8)组,共反馈8个mstna-F1测序结果,其中有3个测序结果在CRISPR4附近出现明显的Indel突变,CRISPR4典型峰图如图5所示,共反馈8个mstna-R1测序结果,其中有3个测序结果在CRISPR8附近出现明显的Indel突变,CRISPR8典型峰图如图6所示。
将验证出有活性sgRNA4对应的所有测序结果与野生型序列进行相互比较后(https://tide.deskgen.com/),得到相对的活性数值,取平均值为6.175%,得到最终的活性率;将验证出有活性sgRNA8对应的所有测序结果与野生型序列进行相互比较后,得到相对的活性数值,取平均值8.4125%,得到最终的活性率。
综合以上实验结果,以斑马鱼胚胎为反应器,体外转录合成的sgRNA4(6.175%)与sgRNA8(8.412%)对斑点叉尾鮰mstna基因可进行有效编辑。建议混合使用2种活性sgRNA。基因组编辑工具使用的浓度建议为:sgRNA的工作浓度(在注射液中的终浓度)为100ng/μL、Cas9蛋白的终浓度为250ng/μL。
以上所述仅是本发明的优选实施方式,应当指出:对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 江苏省淡水水产研究所
<120> 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法
<141> 2020-10-16
<160> 28
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 1
cctagaggtc aaaatcaccg agg 23
<210> 2
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 2
aagcgctcca gacgagaatc cgg 23
<210> 3
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 3
agcgggtaac ggcagcagcg ggg 23
<210> 4
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 4
actgtagact ttgaggactt tgg 23
<210> 5
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 5
actggatcat tgcgcccaag cgg 23
<210> 6
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 6
ctgctcgggc gagtgcgagc agg 23
<210> 7
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 7
acgcgcagaa gttcccacac tgg 23
<210> 8
<211> 23
<212> DNA/RNA
<213> Artificial Sequence
<400> 8
gtgaacaagg caaacccgcg agg 23
<210> 9
<211> 484
<212> DNA/RNA
<213> Artificial Sequence
<400> 9
ttgtcatacc ttatctgccg agcttatgcc ttggtagtgt ttataactct ctgaagaaat 60
gttgcatgtc acctctttct ccttttgaat cctattttcg cagcaaccgt tcctagaggt 120
caaaatcacc gaggtgccga agcgctccag acgagaatcc ggcctcgact gcaacgagct 180
ctcttcagaa ccccgctgct gccgttaccc gctcactgta gactttgagg actttggttg 240
ggactggatc attgcgccca agcggtacaa ggctaactac tgctcgggcg agtgcgagca 300
ggtcgacgcg cagaagttcc cacactggca cctggtgaac aaggcaaacc cgcgaggtac 360
ggccggaccc tgctgcacgc ccaccaaaat gtcccccatc aacatgctct acttcaacca 420
ccgagagcag atcatctacg ggaagatccc ttctatggtc gtggatctct gtggctgcaa 480
ctga 484
<210> 10
<211> 20
<212> DNA/RNA
<213> Artificial Sequence
<400> 10
ttgtcatacc ttatctgccg 20
<210> 11
<211> 20
<212> DNA/RNA
<213> Artificial Sequence
<400> 11
agagatccac gaccatagaa 20
<210> 12
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 12
taatacgact cactataggc ctagaggtca aaatcaccgg ttttagagct agaaatagc 59
<210> 13
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 13
taatacgact cactatagga agcgctccag acgagaatcg ttttagagct agaaatagc 59
<210> 14
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 14
taatacgact cactatagga gcgggtaacg gcagcagcgg ttttagagct agaaatagc 59
<210> 15
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 15
taatacgact cactatagga ctgtagactt tgaggacttg ttttagagct agaaatagc 59
<210> 16
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 16
taatacgact cactatagga ctggatcatt gcgcccaagg ttttagagct agaaatagc 59
<210> 17
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 17
taatacgact cactataggc tgctcgggcg agtgcgagcg ttttagagct agaaatagc 59
<210> 18
<211> 59
<212> DNA/RNA
<213> Artificial Sequence
<400> 18
taatacgact cactatagga cgcgcagaag ttcccacacg ttttagagct agaaatagc 59
<210> 19
<211> 57
<212> DNA/RNA
<213> Artificial Sequence
<400> 19
taatacgact cactatagtg aacaaggcaa acccgcggtt ttagagctag aaatagc 57
<210> 20
<211> 25
<212> DNA/RNA
<213> Artificial Sequence
<400> 20
aaaaaaagca ccgactcggt gccac 25
<210> 21
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 21
ggccuagagg ucaaaaucac cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 22
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 22
ggaagcgcuc cagacgagaa ucguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 23
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 23
ggagcgggua acggcagcag cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 24
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 24
ggacuguaga cuuugaggac uuguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 25
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 25
ggacuggauc auugcgccca agguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 26
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 26
ggcugcucgg gcgagugcga gcguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 27
<211> 105
<212> DNA/RNA
<213> Artificial Sequence
<400> 27
ggacgcgcag aaguucccac acguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uuuuu 105
<210> 28
<211> 103
<212> DNA/RNA
<213> Artificial Sequence
<400> 28
gugaacaagg caaacccgcg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu uuu 103
Claims (2)
1.用于靶向敲除斑点叉尾鮰mstna基因的核苷酸,其特征在于:包括,
如序列SEQ ID NO.4或SEQ ID NO.8所示的CRISPR序列;
如序列SEQ ID NO.24或SEQ ID NO.28中所示的sgRNA;
扩增引物对如序列SEQ ID NO.10和SEQ ID NO.11所示;
用体外转录方法制备如SEQ ID NO.24所示的sgRNA时,使用的正向引物序列如SEQ IDNO.15所示,反向引物序列如SEQ ID NO.20所示;或制备如SEQ ID NO.28所示的sgRNA时,使用的正向引物序列如SEQ ID NO.19所示,反向引物序列如SEQ ID NO.20所示。
2.一种靶向敲除斑点叉尾鮰mstna基因的核苷酸的筛选方法,其特征在于:包括,
设计CRISPR序列,所述CRISPR序列如序列SEQ ID NO.4或SEQ ID NO.8所示;
用所述CRISPR序列制备含目标基因片段的PCR扩增产物,制备目标基因的PCR扩增产物,所述目标基因片段如序列SEQ ID NO.9所示;
将所述含目标基因片段的PCR扩增产物与载体连接、转化后筛选阳性转化子,经克隆摇菌并抽提出包含目的基因的质粒;
根据设计的CRISPR序列,用体外转录方法制备sgRNA;
将所述sgRNA、所述包含目的基因的质粒和Cas9蛋白显微注射斑马鱼受精卵,以斑马鱼受精卵作为反应器筛选编辑斑点叉尾鮰mstna基因的sgRNA序列;所述sgRNA,其序列如SEQID NO.24或SEQ ID NO.28所示;用体外转录方法制备如SEQ ID NO.24所示的sgRNA时,使用的正向引物序列如SEQ ID NO.15所示,反向引物序列如SEQ ID NO.20所示;或制备如SEQID NO.28所示的sgRNA时,使用的正向引物序列如SEQ ID NO.19所示,反向引物序列如SEQID NO.20所示;所述经克隆摇菌并抽提出包含目的基因的质粒,其使用的引物序列包括序列SEQ ID NO.10和SEQ ID NO.11;所述经克隆摇菌并抽提出包含目的基因的质粒,其使用的载体为pGEM-T Easy载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011255641.3A CN112342215B (zh) | 2020-11-11 | 2020-11-11 | 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011255641.3A CN112342215B (zh) | 2020-11-11 | 2020-11-11 | 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112342215A CN112342215A (zh) | 2021-02-09 |
CN112342215B true CN112342215B (zh) | 2024-03-26 |
Family
ID=74363425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011255641.3A Active CN112342215B (zh) | 2020-11-11 | 2020-11-11 | 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112342215B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114875033A (zh) * | 2022-06-29 | 2022-08-09 | 福建省医学科学研究院 | sgRNA、CRISPR/Cas试剂及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1831136A (zh) * | 2005-12-30 | 2006-09-13 | 中国水产科学研究院黄海水产研究所 | 鱼类肌肉生长抑素mstn基因克隆及其基因打靶载体构建 |
CN104531705A (zh) * | 2014-12-09 | 2015-04-22 | 中国农业大学 | 利用CRISPR-Cas9***敲除动物myostatin基因的方法 |
CN110904103A (zh) * | 2019-10-18 | 2020-03-24 | 陕西师范大学 | 一种GRNa基因敲除斑马鱼突变体及其制备方法 |
CN111269943A (zh) * | 2019-08-10 | 2020-06-12 | 湖南文理学院 | 一种通过基因敲除技术增加斑马鱼生长速度的方法 |
-
2020
- 2020-11-11 CN CN202011255641.3A patent/CN112342215B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1831136A (zh) * | 2005-12-30 | 2006-09-13 | 中国水产科学研究院黄海水产研究所 | 鱼类肌肉生长抑素mstn基因克隆及其基因打靶载体构建 |
CN104531705A (zh) * | 2014-12-09 | 2015-04-22 | 中国农业大学 | 利用CRISPR-Cas9***敲除动物myostatin基因的方法 |
CN111269943A (zh) * | 2019-08-10 | 2020-06-12 | 湖南文理学院 | 一种通过基因敲除技术增加斑马鱼生长速度的方法 |
CN110904103A (zh) * | 2019-10-18 | 2020-03-24 | 陕西师范大学 | 一种GRNa基因敲除斑马鱼突变体及其制备方法 |
Non-Patent Citations (1)
Title |
---|
Generation of Myostatin Gene-Edited Channel Catfish (Ictalurus punctatus) via Zygote Injection of CRISPR/Cas9 System;Karim Khalil等;《SCIENTIFIC REPORTS》;20170804;第7卷;第2页第3-4段,第4页第1段,第6页第4段,图1,表1 * |
Also Published As
Publication number | Publication date |
---|---|
CN112342215A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107326046A (zh) | 一种提高外源基因同源重组效率的方法 | |
CN113278619B (zh) | 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法 | |
CN109628613B (zh) | 一种与蛋鸭产蛋和蛋品质性状相关的分子标记及其应用 | |
US7230156B2 (en) | Method for preparing a sterile transgenic carp | |
CN110684777B (zh) | 一段分离的核苷酸序列在肌间刺减少的斑马鱼构建中的应用 | |
CN110541002A (zh) | 一种利用CRISPR/Cas9技术构建斑马鱼asap1b基因敲除突变体的方法 | |
WO2022111124A1 (zh) | 发育正常无肌间刺鱼类新品种培育方法 | |
CN112342214B (zh) | 一种靶向敲除斑点叉尾鮰zbtb38基因的sgRNA序列及其筛选方法 | |
CN111154758A (zh) | 敲除斑马鱼slc26a4基因的方法 | |
CN112342215B (zh) | 一种靶向敲除斑点叉尾鮰mstna基因的sgRNA序列及其筛选方法 | |
CN115058424A (zh) | 一种irf2bpl基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN113817734A (zh) | 一种hectd4基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN113897399A (zh) | 一种scn1lab基因敲除斑马鱼癫痫模型及其应用 | |
CN109055385B (zh) | 一种有效抑制ⅱ型prrsv感染的基因序列及其应用 | |
CN114410808B (zh) | 一种鸡a、k亚群禽白血病遗传抗性分子标记及其应用 | |
CN113621610B (zh) | 一对敲除猪HSPA6基因部分保守区域的sgRNA序列及应用 | |
CN112779259B (zh) | 一种用于精准编辑绵羊OCT4基因的sgRNA、扩增用引物和应用 | |
CN116536327A (zh) | 一种小麦黄花叶病感病基因TaEIF4E及其应用 | |
CN113684209A (zh) | 能有效编辑猪PCBP1基因的sgRNA及其应用 | |
CN113897362A (zh) | 一种scn1lab基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN109628447B (zh) | 特异靶向羊友好位点H11的sgRNA及其编码DNA和应用 | |
CN113957070A (zh) | 一种chd2基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN113897361A (zh) | 一种eef1b2基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN112695034A (zh) | ApoE基因缺失斑马鱼的制备 | |
Koga | Transposition mechanisms and biothechnology applications of the medaka fish tol2 transposable element |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |